Subscribe By RSS
Biogen Idec - Bull Of The Day
By Zacks Investment Research on April 20, 2009 | More Posts By Zacks Investment Research | Author's Website
Biogen Idec (BIIB) posted solid results in the first quarter of 2009, despite the slowdown in Tysabri sales due to fears of PML. We think the Biogen core business will remain strong over the next several quarters. Tysabri prescriptions are showing an improvement and we believe will resume their previous pace shortly.
In the meantime, the name is significant under-valued and would be a very attractive takeout candidate for a large-cap pharmaceutical company looking for a great phase III pipeline. We expect 2009 to be an eventful year on the pipeline front.
As investors become more comfortable with both Tysabri trends and emerging pipeline, we believe shares will recover back into the low $60 s. At today s price, the name is too attractive to ignore.
Subscribe by RSS 
Subscribe by Email
Email This Post To A Friend
What Is Ron Paul’s Real Agenda When He Talks About Auditing The Fed 
Physical Gold, Silver And Oil Out-Performing Their Stocks? 
Forex Trading Ideas: Is Sterling About To Get Pounded? - Chart Of The Week: No More Easy Money For Volatility Sellers?
Silver Hits New Highs At Top Of Uptrend Channel
- Stocks Moving Off Highs But Holding Onto Notable Gains - U.S. Commentary - 44 mins ago
- Bay Street Market Gains More Than 1% - Canadian Commentary - 1 hr ago
- Stocks Give Back Some Ground But Show Continued Strength - U.S. Commentary - 1 hr ago
- Existing Home Sales Jump By Much More Than Expected In October - 2 hrs ago
- Stocks Seeing Substantial Strength In Mid-Morning Trading - U.S. Commentary - 2 hrs ago
